-
Mashup Score: 0ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure - 12 month(s) ago
The findings, from a small, prematurely stopped trial, need to be confirmed in larger studies, one expert says.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Low-dose DOACs in SVT - 1 year(s) ago
Implied Consent Form Study Title: Extended anticoagulation for secondary prevention of recurrent venous thromboembolism using low-dose direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice of thrombosis specialists. Principal Investigator: Dr. Aurélien Delluc, Division of Hematology at The Ottawa Hospital; Phone: 613-737-8899 extension 71069; Fax:…
Source: survey.toh.on.caCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation - 1 year(s) ago
Oral anticoagulation therapy has evolved beyond vitamin K antagonists to include oral direct thrombin inhibitors and factor Xa inhibitors. Collectively known as ‘direct oral anticoagulants’, this class of medications represents the current standard of care for the prevention and treatment of common thrombotic disorders, including atrial fibrillation and venous thromboembolism. Medications that…
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2
Researchers sought to compare the safety and efficacy of direct oral anticoagulants with vitamin-K antagonists in patients with thrombotic antiphospholipid syndrome.
Source: The Cardiology AdvisorCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial): - 1 year(s) ago
IntroductionTo date, no randomized trials have evaluated the efficacy of oral anticoagulation in patients with left ventricular thrombi (LVT). However, observational studies conducted in the pre-reperfusion era support the use of vitamin K antagonists to decrease the incidence of systemic embolization. As a result, societal guidelines recommend vitamin K antagonists for patients with LVT. We…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Warfarin best for thrombotic antiphospholipid syndrome? - 1 year(s) ago
A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic antiphospholipid syndrome, a new meta-analysis suggests.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Warfarin Best for Thrombotic Antiphospholipid Syndrome? - 1 year(s) ago
Patients with thrombotic antiphospholipid syndrome appear better treated with a vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, a new meta-analysis suggests.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves? - American Journal of Cardiovascular Drugs - 1 year(s) ago
Mechanical heart valves (MHVs) replacement is recommended for younger patients with valvular heart disease because of the durability of the mechanical valve, but these patients need antithrombotic therapy for a lifelong time. The vitamin K antagonist (VKA) warfarin is the only approved oral antithrombotic drug for patients with MHVs. The direct oral anticoagulants (DOACs), including direct…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation - 1 year(s) ago
AbstractAims. Beyond 1 year after percutaneous coronary intervention (PCI), guidelines recommend anticoagulant monotherapy in patients with atrial fibrillation
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Head-to-head Efficacy and Safety of Rivaroxaban, Apixaban and Dabigatran in an Observational Nationwide Targeted Trial - 1 year(s) ago
AbstractAims. The advantages of direct oral anticoagulants (DOACs) over warfarin are well established in atrial fibrillation (AF) patients, however, studies tha
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
Researchers at #EuroPCR reported a composite of thromboembolic events, device-related thrombus, and major bleeding through 3 months was reduced w/ low-dose #DOAC vs #DAPT w/ aspirin & clopidogrel following #LAAO. @ToddNeale has the full story: https://t.co/CwkuT99i7c @TCTMD